Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C

BACKGROUND: Direct-acting antivirals (DAAs) for chronic hepatitis C (CHC) treatment are tolerable and highly effective in a shorter period of time than before. However, resistance-associated variants (RAVs) can affect the efficacy of DAAs. The aim of this study was to investigate the real-life preva...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jung Hwan, Lee, Jung Il, Lee, Kwan Sik, Kim, Ja Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571669/
https://www.ncbi.nlm.nih.gov/pubmed/28836992
http://dx.doi.org/10.1186/s12985-017-0826-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571669/
https://www.ncbi.nlm.nih.gov/pubmed/28836992
http://dx.doi.org/10.1186/s12985-017-0826-1

Ejemplares similares